US REGULATORY RECORDS
- FDA API DMF records
- 33
- Active (A)
- 9
- Inactive (I)
- 24
FDA list cutoff:
ACTIVE PHARMACEUTICAL INGREDIENT
Research Ibuprofen API through FDA DMF and China CDE records. Compare reported companies, review filing statuses and confirm the free-acid identity before preparing your sourcing shortlist.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
This Ibuprofen profile covers the ordinary free acid, CAS 15687-27-1. Dexibuprofen, other single-enantiomer material, sodium, lysine and arginine salts, finished dosage forms and processed mixtures are excluded. Selection follows reported names and subjects; the registries do not independently verify the CAS or batch composition of every entry.
Ibuprofen registry coverage: 33 FDA API-related DMF entries and 14 CDE API registrations selected by substance name. Browse the free samples, then use a subscription to search, filter and export the complete available Ibuprofen records.
FDA list cutoff:
CDE export captured:
0 documented company-name correspondences
The registries have different snapshot dates and status definitions. Counts describe records, not qualified suppliers. Company fields retain their original wording, including repeated parties. No cross-registry company-name correspondences are documented for this profile.
$19.00 per month
$149.00 per year
Billed $149.00 every year
This profile: 33 FDA DMF records, 14 CDE registrations and 0 company-name correspondences.
One personal account can access subscription datasets currently available on APIRFQ. Coverage varies by product. This does not include quotations, supplier qualification or live monitoring.
Use the Ibuprofen registry tables below to inspect original holder and company fields. No cross-registry company-name correspondences are documented. Similar names, translations or membership of the same group do not verify an identical legal entity or manufacturing site.
Free previewShowing 0 sample records of 0.
0 company-name correspondences
No exact company-name correspondences are documented for these snapshots.
Other records remain available below and in the registry tables. A missing name correspondence does not imply a missing registration.
Original reported names are preserved. A CDE company field may contain several named parties; their roles are not inferred from name order. Unmatched names are not treated as ineligible suppliers.
US REGULATORY RECORDS
Inspect Ibuprofen DMF holders, original subjects, submission dates and activity status. Included subjects identify the API or its manufacture; a Type II filing alone does not establish supplier qualification or current material availability.
9Active (A)
24Inactive (I)
A = active; I = inactive. DMFs are neither approved nor disapproved by FDA. These entries do not establish supplier qualification, manufacturing-site approval, dossier access or current availability.
Free previewShowing 3 sample records of 33.
Free preview
More records available with a subscription: 30.
CHINA REGULATORY RECORDS
Inspect the Ibuprofen registration numbers, original Chinese company fields and reported review status. Expand each Ibuprofen entry to see all source columns, including unfilled cells, packaging and approval references.
12Approved or qualifying prior approval (A)
2Technical review not passed or unlinked (I)
CDE A and I describe Chinese review status independently of FDA activity. A can follow joint review, transfer of qualifying prior approvals or independent API review. I means technical review has not been passed or the material has not been linked to a formulation registration. Reported validity dates and status do not independently establish current supplier qualification.
Free previewShowing 3 sample records of 14.
Free preview
More records available with a subscription: 11.
Ibuprofen is a monocarboxylic acid with a 4-isobutylphenyl group on a propionic-acid backbone. This profile uses CAS 15687-27-1 for the ordinary free acid. Dexibuprofen identifies the S enantiomer and is excluded. Sodium, lysine and arginine salts are separate chemical forms. Reference identifiers define this page; a registry name alone does not confirm the chemical composition of a filing.
Reference identity; CAS is not independently confirmed for each registry entry.
Ibuprofen reference properties describe the neutral free acid. A shared formula does not distinguish isolated enantiomers. Confirm chemical form, assay basis, impurity limits and particle-size requirements against the proposed material specification and analytical documentation.
Check the Ibuprofen reference structure, distinguish the isolated enantiomer and review the meaning of registry records.
Check free-acid identifiers, formula and reference molecular masses.
Cross-check the substance name and CAS number.
Distinguish the S enantiomer from ordinary Ibuprofen material.
Read how DMFs support applications and why activity is not approval.
Ibuprofen here means the ordinary free acid, CAS 15687-27-1, rather than an isolated enantiomer or salt. ChEBI reports formula C13H18O2, molecular weight 206.285 g/mol and exact mass 206.13068 Da. KEGG cross-checks the name and CAS. These are reference identifiers, not independently verified CAS assignments for every filing.
Dexibuprofen is the S enantiomer. This Ibuprofen selection excludes subjects naming dexibuprofen, S-ibuprofen or S-(+)-ibuprofen and CDE entries named 右布洛芬 or 右旋布洛芬. Molecular formula alone cannot distinguish these materials. Confirm stereochemical identity in the proposed specification before treating two materials as equivalent.
No. Sodium, lysine and arginine salts, finished tablets and capsules, coated or diluted preparations and direct-compression granules are outside this Ibuprofen free-acid selection. A salt or prepared mixture should be assessed against its own chemical identity and composition rather than counted as another record for the same API.
The selection includes ordinary Ibuprofen subjects, pharmacopoeial name variants and the manufacturing-procedure filing DMF 4329. It excludes facility-control filing 2720, plasma-analysis filing 9661 and subjects identifying other chemical forms or preparations. Type II includes more than drug substances, so the subject is checked alongside the type.
No. FDA A means active and I means inactive. FDA states that DMFs are neither approved nor disapproved. An active Ibuprofen entry does not establish an approved supplier, a qualified manufacturing site, access to the dossier or current stock. Verify the current filing and the documentation needed for your application.
CDE inclusion requires the exact name 布洛芬. Original company names, addresses, packaging, dates, review codes and approval references are preserved across all eleven fields. The CSV has no CAS column, so selection does not independently confirm chemical identity. Repeated parties within one company field do not establish extra suppliers.
CDE A can reflect joint technical review, transfer of qualifying prior approvals or independent API review. I covers technical review not passed or a registration not yet linked to a formulation. These are separate from FDA activity codes. Read the Ibuprofen record in its Chinese regulatory context and verify its current status.
No. FDA records use the June 30, 2026 list cutoff; CDE records use the October 5, 2026 export. Neither snapshot establishes current supply, batch quality or site qualification. For an Ibuprofen sourcing review, obtain the proposed specification, certificate of analysis, manufacturing-site details and applicable dossier authorization directly from the relevant company.
No verified cross-registry company-name correspondences are documented for this Ibuprofen profile. Original holder and company fields remain available for comparison. Similar names, translated names or a shared corporate group do not establish that the same legal entity or manufacturing site is involved.
The free Ibuprofen preview contains sample rows from each available registry, with CSV samples of those rows. A subscription opens the complete available dataset for search, status filtering and CSV export. Coverage refers to these dated source selections; it does not include quotations, supplier qualification or live registry monitoring.
Primary references for chemical identity, registration records and status definitions. Open each source to check its scope and current information.
EMBL-EBI
Provides the free-acid formula, reference masses, InChIKey and SMILES structure.
“2-[4-(2-methylpropyl)phenyl]propanoic acid”
EMBL-EBI
IUPAC name in ChEBI CHEBI:5855; properties and structure come from the same entry.
KEGG
Cross-checks the Ibuprofen name and CAS 15687-27-1.
“Ibuprofen (JP19/USP/INN)”
KEGG
Name field in KEGG Drug D00126; CAS is reported in the same entry.
EMBL-EBI
Identifies dexibuprofen as the separate S-enantiomer entry used to distinguish excluded single-enantiomer filings.
“dexibuprofen”
EMBL-EBI
ChEBI name in CHEBI:43415; the stereochemical structure identifies the S enantiomer.
U.S. Food and Drug Administration
Displayed records come from the supplied Q2 workbook with a June 30, 2026 cutoff. The official page now offers a later quarterly list.
“PROCEDURES FOR THE MANUF OF IBUPROFEN”
U.S. Food and Drug Administration
Exact subject of DMF 4329 in worksheet 2Q2026-EXCEL of the supplied workbook.
U.S. Food and Drug Administration
Explains DMF use and review. A listing or active status does not establish approval of a supplier or product.
“Are neither approved nor disapproved.”
U.S. Food and Drug Administration
FDA statement about DMFs; their technical contents are reviewed with applications that reference them.
U.S. Food and Drug Administration
Type II is broader than APIs, so the reported subject must also be checked.
“Type II Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation; or Drug Product”
U.S. Food and Drug Administration
FDA Type II category heading.
Center for Drug Evaluation, National Medical Products Administration
The October 5, 2026 export supplies the name-selected Ibuprofen registrations, original company fields, status codes and empty cells.
“布洛芬”
Center for Drug Evaluation, National Medical Products Administration
Exact reported substance name for the included registrations in the supplied CSV, including Y20260000554.
Liaoning Medical Products Administration
Official explanation of A and I, including joint review, qualifying prior approvals and independent API review.
“未通过技术审评或尚未与制剂注册进行关联的标识为“I”。”
Liaoning Medical Products Administration
Regulator explanation published February 18, 2025: I covers technical review not passed or a registration not yet linked to a formulation.
Compare Ibuprofen registry names, statuses and chemical-form boundaries using the free samples. Subscribe to search, filter and export the complete available FDA and CDE records for your sourcing review.
Complete data requires an active subscription. Already subscribed? Sign in to access your data.
Report an Ibuprofen data issue with the page address, registry number and supporting official evidence. APIRFQ support handles data corrections. Contact the relevant company separately about material specifications, dossier access or supply.
Contact data support